CAM
CBIO

ClariVest Asset Management’s Crescent Biopharma CBIO Stock Holding History

ClariVest Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,688
Closed -$508K – 780
2021
Q1 		$508K Buy
1,688
+388
+30% +$139K 0.02% 410
2020
Q4 		$489K Sell
1,300
-19
-1% -$6.66K 0.02% 387
2020
Q3 		$405K Sell
1,319
-82
-6% -$31.3K 0.01% 378
2020
Q2 		$527K Buy
+1,401
New +$397K 0.01% 395

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClariVest Asset Management's CBIO Position: Q2 2021 in Review

ClariVest Asset Management sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 1,688 shares — an estimated $508K sold.

ClariVest Asset Management first reported a position in CBIO in Q2 2020 and held it in 4 quarters. The position peaked at $527K in Q2 2020. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • ClariVest Asset Management reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 1,688 Crescent Biopharma shares in Q2 2021, an estimated $508K.
  • ClariVest Asset Management first reported a position in Crescent Biopharma in Q2 2020 and held it in 4 quarters.
  • ClariVest Asset Management's Crescent Biopharma position peaked at $527K in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.